GlassScriptPhysician profile
Rakesh N Parikh
NPI 1922072503
$4,370.46
in general payments reported to CMS, 2019-2025
42 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $234 · 2021: $484 · 2022: $829 · 2023: $542 · 2024: $709 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $482.51 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $440.28 | 2021-2025 | Verquvo |
| Amgen INC. | $392.81 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $338.07 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $232.05 | 2022-2025 | |
| Galderma Laboratories, L.P. | $226.22 | 2019 | |
| Urgo Medical North America, LLC | $154.00 | 2025 | Urgoclean Ag |
| Pfizer INC. | $148.13 | 2019-2021 | |
| Sk Life Science, INC. | $140.01 | 2021-2023 | Xcopri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.15 | 2019-2022 | |
| Inari Medical, INC. | $122.16 | 2021 | |
| Kerecis Limited | $116.00 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $112.48 | 2019 | |
| Vanda Pharmaceuticals INC. | $104.96 | 2025 | Fanapt |
| Mimedx Group, INC. | $104.33 | 2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.